GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enzymotec Ltd (NAS:ENZY) » Definitions » Return-on-Tangible-Equity

Enzymotec (Enzymotec) Return-on-Tangible-Equity : 1.28% (As of Sep. 2017)


View and export this data going back to 2013. Start your Free Trial

What is Enzymotec Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Enzymotec's annualized net income for the quarter that ended in Sep. 2017 was $1.70 Mil. Enzymotec's average shareholder tangible equity for the quarter that ended in Sep. 2017 was $132.50 Mil. Therefore, Enzymotec's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2017 was 1.28%.

The historical rank and industry rank for Enzymotec's Return-on-Tangible-Equity or its related term are showing as below:

ENZY's Return-on-Tangible-Equity is not ranked *
in the Biotechnology industry.
Industry Median: -48.28
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

Enzymotec Return-on-Tangible-Equity Historical Data

The historical data trend for Enzymotec's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzymotec Return-on-Tangible-Equity Chart

Enzymotec Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Return-on-Tangible-Equity
Get a 7-Day Free Trial 15.50 15.00 6.40 5.09 -2.16

Enzymotec Quarterly Data
Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.95 -12.27 0.07 -6.89 1.28

Competitive Comparison of Enzymotec's Return-on-Tangible-Equity

For the Biotechnology subindustry, Enzymotec's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enzymotec's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enzymotec's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Enzymotec's Return-on-Tangible-Equity falls into.



Enzymotec Return-on-Tangible-Equity Calculation

Enzymotec's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2016 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2016 )  (A: Dec. 2015 )(A: Dec. 2016 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2016 )  (A: Dec. 2015 )(A: Dec. 2016 )
=-2.923/( (135.601+135.573 )/ 2 )
=-2.923/135.587
=-2.16 %

Enzymotec's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2017 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Sep. 2017 )  (Q: Jun. 2017 )(Q: Sep. 2017 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Sep. 2017 )  (Q: Jun. 2017 )(Q: Sep. 2017 )
=1.696/( (132.876+132.12)/ 2 )
=1.696/132.498
=1.28 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2017) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Enzymotec  (NAS:ENZY) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Enzymotec Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Enzymotec's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Enzymotec (Enzymotec) Business Description

Traded in Other Exchanges
N/A
Address
Enzymotec Ltd is nutritional and food ingredients company. It develops and manufactures nutritional ingredients and medical foods based on proprietary technologies. Its product portfolio includes Infat, K-Real, Enzy PS solutions, Vayacog, Vayarin and Vayaroll. The company has Nutrition and Vaya Pharma reportable segments. It derives majority of its revenues from Nutrition segment. The firm mainly operates in America, Europe, Australia, Asia, and Israel.

Enzymotec (Enzymotec) Headlines

From GuruFocus

Julian Robertson Adds to Multiple Positions in 3rd quarter

By Tiziano Frateschi Tiziano Frateschi 12-20-2016

Tiger Management Founder Julian Robertson Ups Stake in Enzymotec

By Kyle Ferguson Kyle Ferguson 12-07-2015

Julian Robertson Cuts Half of Stake in Paulson-Backed Company

By Holly LaFon Holly LaFon 07-01-2016